Cargando…
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Immune checkpoint inhibitors (ICPis) have revolutionized cancer therapy with broad activities against a wide range of malignancies. However, in many malignancies their efficacy remains limited due to the primary resistance. Furthermore, a high percentage of patients develop progression due to the se...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410194/ https://www.ncbi.nlm.nih.gov/pubmed/30678257 http://dx.doi.org/10.3390/medsci7020014 |